Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 122

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 122
---
 costs or management overhead for our business; and •any of these factors could have a negative impact on our business, results of operations or financial position. Acquisitions are also accompanied by the risk that obligations and liabilities of an acquired business may not be adequately reflected in the historical financial statements of that business and the risk that historical financial statements may be based on assumptions, which are incorrect or inconsistent with our assumptions or approach to accounting policies. The acquisition and integration of businesses may not be funded or managed effectively and any failure to manage the integration process could lead to disruptions in the overall activities of the Company, a loss of clients and revenue and increased expenses. In addition, in order to finance any acquisitions, investments, joint 38 ventures or other relationships, we may need to raise additional funds through securities offerings, credit facilities, asset sales or collaborations or licensing agreements. To the extent these financing transactions call for the issuance of shares of our capital shares, our existing shareholders would experience dilution in their relative ownership of our capital shares. Additional funds from capital -raisingtransactions may not be available when needed, on acceptable terms or at all. Any inability to fund any acquisitions, investments, or strategic relationships we pursue could cause us to forfeit opportunities we believe are promising or valuable, which could harm our prospects. Further, integration of an acquired business or technology could involve significant difficulties and could require management and capital resources that otherwise would be available for ongoing development of our existing business or pursuit of other opportunities. We may also acquire contingent liabilities in connection with the acquisitions of a business, which may be material, and any estimates we might make regarding any acquired contingent liabilities and the likelihood that these liabilities will materialize could differ materially from the liabilities actually incurred. These circumstances could materially harm our business, financial condition, results of operations and growth prospects. Ethical, legal and social concerns related to the use of genetic information could reduce demand for our genetic tests. Our products may be used to provide genetic information about humans and other organisms. The information obtained from our products could be used in a variety of applications, which may have underlying ethical, legal and social concerns regarding privacy and the appropriate uses of the resulting information, including preimplantation genetic screening of embryos, prenatal genetic testing or genetic engineering, or testing genetic predisposition for certain medical conditions, particularly those that have no known cure. Our customers’ implementation of our products to provide their own products and services may raise such concerns and affect our own reputation. U.S. and international governmental authorities could, for social or other purposes, call